Advanced Search

 

Study ID Status Title Patient Level Data
VRA107438 Terminated A double-blind, randomised, placebo controlled, single dose, two-period crossover study to investigate the therapeutic potential of the TRPV1 antagonist SB-705498 in treatment of subjects with rectal hypersensitivity including irritable bowel syndrome.
VRX-RET-E22-101 Completed Single-Dose Pharmacokinetics of Retigabine in Healthy Subjects and Patients with Various Degrees of Renal Insufficiency Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-101SR Completed Open-Label, Single-Dose, 8-Period Study to Evaluate the Pharmacokinetics, Safety and Tolerability of a 400 mg Dose of Retigabine Sustained-Release Formulations in Seven Dosing Periods Versus a 200 mg Dose of Retigabine Immediate-Release Formulation in One Dosing Period in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-102 Completed Single-Dose Pharmacokinetics Study of Retigabine in Patients with Various Degrees of Hepatic Impairment Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-103 Completed A Double-Blind Randomized Parallel-group Trial to Define the ECG Effects of Retigabine Using a Maximum Tolerated Dose Compared with Placebo and Moxifloxacin (a Positive Control) in Healthy Men and Women: A Thorough ECG Trial Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-104 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-way Crossover Food Effect, Safety and Tolerability Study of a 400-mg Dose of the Retigabine Market Image Tablet in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-105 Completed Comparative, Randomized, Open-Label, Single-Dose, 2-Way Crossover Bioavailability, Safety and Tolerability Study of a 400mg Dose of Retigabine Administered as the Clinical Trials Formulation and the Market Image Formulation in Healthy Adult Male Subjects Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-106 Completed A Pharmacokinetic Interaction Study Evaluating the Effect of Repeated Retigabine Dosing on the Pharmacokinetics of Oral Contraceptives in Healthy Adult Female Volunteers Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-107 Completed A Randomized, Partially Double-Blind, Four-Way Crossover Study to Determine the Effects of a Single Dose of Retigabine Combined with a Single Dose of Alcohol Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-108 Completed A Randomized, Double-Blind, Placebo- and Active-Controlled Crossover Study to Evaluate the Abuse Potential of Retigabine in Recreational Polydrug Users Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-301 Completed A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study to Determine the Efficacy and Safety of Retigabine (1200 mg/day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-302 Completed Randomized, Double-Blind, Placebo-Controlled, Multicenter, Parallel-Group Phase 3 Study - Determine Efficacy and Safety of Two Doses of Retigabine (900 Mg/Day and 600 Mg/Day) Used as Adjunctive Therapy in Refractory Epilepsy Patients with Partial-Onset Seizures Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-303 Completed A multicenter, open-label, long-term, safety, tolerability and efficacy study of retigabine in adult epilepsy patients with partial-onset seizures (Extension of study VRX-RET-E22-301)
VRX-RET-E22-MR103 Completed Open-Label Study to Evaluate the Pharmacokinetics,Safety and Tolerability of Retigabine Following Single and Multiple Dose Administration of Two Different Modified Release Formulations Compared to Single Dose Administration of One Immediate Release Formula Study Listed on ClinicalStudyDataRequest.com
VRX-RET-E22-NP201 Completed A Randomized, Double-Blind, Placebo-Controlled, Phase 2a Proof-of-Concept Study to Evaluate the Efficacy of Maximally Tolerated Doses of Retigabine vs. Placebo in Reducing the Pain Associated with Post-Herpetic Neuralgia Study Listed on ClinicalStudyDataRequest.com
W2650782 Completed A pharmacokinetic study of two oral formulations of orlistat
W2651062 Completed A Study to Assess the Pharmacodynamic Equivalence of Two Orlistat Dosage Forms
W3600586 Completed The effects of weight reduction with orlistat vs. placebo on changes in body composition
W3680604 Completed A study to assess the pharmacologic equivalence of two orlistat dosage forms
W3730613 Completed A Dose-Ranging Study of a Tablet Formulation of Orlistat
W5350856 Completed Survey on the pharmacy follow up of Alli purchasers
W7781293 Completed An Exploratory Study to Measure the Effect of Two Dietary Fibers on Satiety and Glycemic Parameters
W91-016 Completed The Pharmacokinetics and Tolerability of Ondansetron 4mg Given as an Intramuscular Injection
WELL 029 Completed Multicenter Evaluation of the Efficacy and Safety of Low Doses of Wellbatrin vs. Placebo in Depressed Inpatients
Well 08 Completed Phase II Placebo-Controlled Evaluation of Efficacy: Multiclinic Study

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.